Mercredi 25 Mars

0

Mercredi 25 Mars

Sessions simultanées de communications orales : 9 h – 10 h 30.

Session 14 : Pharmacocinétique – Pharmacologie clinique Salle BOFFRAND

Abstracts

Modérateurs :??? 1/ Assessment of CYP2D6 and CYP2C19 activity in vivo in man : a \”cocktail\” study using dextromethorphan and proguanil, alone and in combination. Tennezé L, Ragueneau I, Poirier JM, Roux A, Lebot M, Funck-Brentano C. 137 2/ The genetic variant A of human alpha 1-acid glycoprotein limits the blood to brain transfer of drugs it binds – pharmacological and clinical consequences. Jolliet-Riant P, Boukef MF, Duché JC, Simon N, Tillement JP. 138 3/ Three psoralens kinetics in dermis ; an ex vivo study by microdialysis. Muret P, Mary S, Makki S, Viennet C, Henry JC, Kantelip JP, Humbert P. 139 4/ Population pharmacokinetic of clomipramine in depressive patients : a prospective study. Haffen E, Paintaud G, Sechter D, Bizouard P, Bechtel PR. 140 5/ Effects of single and multiple doses of fluvoxamine and buspirone on choice reaction time, pupilary diameter, temperature and endocrine response in healthy volunteers. Rihet P, Soubrouillard C, Hasbroucq T, Possamaï CA, Jouve E, Blin O. 141 6/ Increased in vitro arachidonic acid metabolism in sudden infant death syndrome.

Tréluyer JM, Benech H, Colin I, Pruvost A, Chéron G, Cresteil T. 142

Session 15 : Antalgiques / Anti-inflammatoires /Neuropeptides Salle GALLE

Abstracts

Modérateurs :??? 1/ S 19812 : a novel dual inhibitor of cyclooxygenases and lipoxygenase with an excellent gastric tolerance. Tordjman C, André N, Bresson Y, Picaud N, Droual M, Sauveur F, Wierzbicki M, Bonnet J. 143 2/ Neuropeptide FF and opioid tolerance and dependence in mice. Gelot A, Francés B, Zajac JM. 144 3/ A UDP-glucuronosyltransferase activity is increased by inflammation in rabbit synovial membrane. Ferrari L, Martin A, Magdalou J, Pottie P, Gillet P, Lapicque F, Netter P, Batt AM. 145 4/ Chondroprotection by no synthases inhibitors : from in vitro screening to in vivo efficacy. Cipolletta C, Presle N, Jouzeau JY, Terlain B, Netter P. 146 5/ Inhibitory effects of adenosine receptor agonists on the release of CGRP, but not substance P, from the rat spinal cord. Bourgoin S, Mauborgne A, Polienor H, Hamon M, Cesselin F. 147 6/ Could the quantitative analyse of spontaneous ultrasonic vocalizations in chronic painful rat be a pharmacological pain test ?

Jourdan D, Ardid D, Chapuy E, Eschalier A, Lavarenne J. 148

Session 16 : Pharmacologie cardiovasculaire Salle LEOPOLD

Abstracts

Modérateurs :??? 1/ Endothelial regrowth in vivo is not modified by addition of L-arginine or L-name : Results in a rabbit balloon injury model. Six I, Van Belle E, Bordet R, Corseaux D, Dupuis B, Bauters C, Bertrand ME. 149 2/ Characterisation of the pertussis toxin-sensitive G-proteins in rat tail artery and aortic smooth muscle. Petitcolin MA, Spitzbarth E, Bueb JL, Capdeville-Atkinson C, Tschirhart EJ. 150 3/ Delayed coronary endothelial protective effects of monophosphoryl lipid a after ischemia and reperfusion in rats. Richard V, Danielou E, Kaeffer N, Thuillez C. 151 4/ Effects of angiotensin converting enzyme inhibition (ACEI) and selective angiotensin II AT1 receptor antagonism (AT1-) on coronary flow reserve in postischemic heart failure in rats. Gervais M, Domergue V, Lesage M, Richer C, Giudicelli JF. 152 5/ Activation of no-synthase-type I by angiotensin II in vascular smooth muscle from spontaneously hypertensive rats (SHR). Boulanger CM, Heymes C, Benessiano J, Geske RS, Lévy BI. 153 6/ Effects of calcium antagonist mibefradil on large arteries in spontaneously hypertensive rats.

Lacolley P, Boutouyrie P, Koffi I, Bézie Y, Boumaza S, Koen R, Laurent S. 154